The Hemophilia A Market is anticipated to evolve immensely in the coming years owing to the rise in the prevalent population of Hemophilia A, the rise in healthcare spending across the world, the expected entry of premium price assets such as gene therapy, siRNA, and bispecific antibodies, and the expected readily uptake of recently approved therapies.
DelveInsight’s “Hemophilia A Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hemophilia A market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Hemophilia A drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Hemophilia A treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Hemophilia A: An Overview
Hemophilia A is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor VIII. Without enough factor VIII, the blood cannot clot properly to control bleeding. Although it is passed down from parents to children, about 1/3 of cases found have no previous family history.
It is caused by an inherited X-linked recessive trait, with the defective gene located on the X chromosome. Females have two copies of the X chromosome. So if the factor VIII gene on one chromosome does not work, the gene on the other chromosome can do the job of making enough factor VIII.
People with hemophilia A bleed longer than other people. Bleeds can occur internally, in joints and muscles, or externally, from minor cuts, dental procedures, or injuries. The frequency of the bleeds and the severity of those bleeds depend on how much FVIII a person produces naturally. Normal levels of FVIII range from 50% to 150%. Levels below 50% – or half of what is needed to form a clot – determine a person’s symptoms.
Individuals with the severe form of hemophilia A can experience spontaneous bleeding into any organ including the kidneys, the gastrointestinal tract, and the brain (intracranial bleeding). Genitourinary and gastrointestinal bleeding may respectively cause blood in the urine (hematuria) and black or bloody stools (melena, hematochezia).
Hemophilia A Market Key Facts
The total market size of Hemophilia A in the United States is expected to increase with a CAGR of 8.5% during the study period (2019–2032).
The total market size of Hemophilia A in EU5 is expected to increase with a CAGR of 7.6% during the study period (2019–2032).
The total market size of Hemophilia A in Japan is expected to increase with a CAGR of 5.1% during the study period (2019–2032).
According to the estimates, the highest market size of Hemophilia A is from the United States in 2021.
Among the EU5 countries, France has the maximum revenue share followed by the United Kingdom in 2021 while Spain has the lowest market share.
The market size of Hemophilia A in Japan is USD 956 million in 2021.
The total prevalent population of Hemophilia A in the 7MM comprised 45,149 cases in 2021.
The total prevalent population of Hemophilia A in the United States is 14,146 in 2021.
The United States contributed to the largest prevalent population of Hemophilia A, accounting for ~ 31% of the 7MM in 2021.
In the EU5 countries, the diagnosed prevalence of Hemophilia A was found to be maximum in France, followed by the UK. While, the least number of cases were found in Spain, in 2021.
Some of the leading pharma giants in the Hemophilia A Market include BioMarin Pharmaceutical, Roche (Spark Therapeutics), ApcinteX, Novo Nordisk, Sanofi (Genzyme), Alnylam Pharmaceuticals, Pfizer, Sangamo Therapeutics, Bayer, Ultragenyx Pharmaceutical, and others.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Hemophilia A pipeline therapies. It also thoroughly assesses the Hemophilia A market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Hemophilia A drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Hemophilia A Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Hemophilia A epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Hemophilia A epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Hemophilia A Epidemiology, Segmented as –
Total Diagnosed Prevalent Pool of Hemophilia A in the 7MM [2019–2032]
Treated Prevalent Pool of Hemophilia A in the 7MM [2019–2032]
Severity-specific Prevalent Pool of Hemophilia A in the 7MM [2019–2032]
Inhibitor-specific Prevalent Pool of Hemophilia A in the 7MM [2019–2032]
Hemophilia A Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Hemophilia A market or expected to be launched during the study period. The analysis covers the Hemophilia A market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Hemophilia A drugs based on their sale and market share.
The report also covers the Hemophilia A pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Hemophilia A companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Hemophilia A Market Will Evolve and Grow by 2032 @
Hemophilia A Therapeutics Analysis
Mostly the available treatments for hemophilia A focus on replacing the missing protein, FVIII (8), so the patient can form a clot, and reduce or eliminate the bleeds associated with the disorder. Treatments that work to prevent bleeding through new mechanisms have recently come to the market or are under development. People with hemophilia A have several different medication options for treatment.
Generally, Hemophilia A patients are provided with “On Demand” and “Prophylaxis” treatment. But Prophylaxis treatment option has gained importance in comparison to the on-demand treatment options.
The mainstay treatment option has long been FVIII replacement therapy. Initially, FVIII replacement was accomplished by donated whole blood, subsequently by plasma, and currently by recombinant human FVIII (rFVIII) replacement therapies, which revolutionized the treatment of Hemophilia A.
Several major pharma and biotech companies are developing therapies for Hemophilia A. Currently, Novo Nordisk is leading the therapeutics market with its Hemophilia A drug candidates in the most advanced stage of clinical development.
Hemophilia A Companies Actively Working in the Therapeutics Market Include
Alnylam Pharmaceuticals, ApcinteX, ApcinteX Ltd., Bayer, BioMarin, BioMarin Pharmaceutical, Catalyst Biosciences, Centessa Pharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Chugai Pharmaceutical, CSL Behring, Dimension Therapeutics, Expression Therapeutics, LLC, Hoffmann-La Roche, Intellia Therapeutics, Kymab, Novo Nordisk, Octapharma, Pfizer, Poseida Therapeutics, Regeneron Pharmaceuticals, Roche (Spark Therapeutics), Sangamo Therapeutics, Sanofi Genzyme, Shire, Sinocelltech Ltd., Spark Therapeutics, Staidson Beijing BioPharmaceuticals, Ultragenyx Pharmaceutical, and many others.
Emerging and Marketed Hemophilia A Therapies Covered in the Report Include:
BIVV001: Sanofi in collaboration with Sobi
Concizumab: Novo Nordisk
Fitusiran: Alnylam Pharmaceuticals/Sanofi Genzyme
Valoctocogene roxaparvovec: BioMarin Pharmaceuticals
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Hemophilia A Competitive Intelligence Analysis
4. Hemophilia A Market Overview at a Glance
5. Hemophilia A Disease Background and Overview
6. Hemophilia A Patient Journey
7. Hemophilia A Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Hemophilia A Treatment Algorithm, Current Treatment, and Medical Practices
9. Hemophilia A Unmet Needs
10. Key Endpoints of Hemophilia A Treatment
11. Hemophilia A Marketed Therapies
12. Hemophilia A Emerging Drugs and Latest Therapeutic Advances
13. Hemophilia A Seven Major Market Analysis
14. Attribute Analysis
15. Hemophilia A Market Outlook (In US, EU5, and Japan)
16. Hemophilia A Companies Active in the Market
17. Hemophilia A Access and Reimbursement Overview
18. KOL Views on the Hemophilia A Market
19. Hemophilia A Market Drivers
20. Hemophilia A Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Childhood Atropine For Myopia Progression Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Childhood Atropine For Myopia Progression market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Childhood Atropine For Myopia Progression market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States